BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van Malenstein H, van Pelt J, Verslype C. Molecular classification of hepatocellular carcinoma anno 2011. Eur J Cancer. 2011;47:1789-1797. [PMID: 21612914 DOI: 10.1016/j.ejca.2011.04.027] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 5.1] [Reference Citation Analysis]
Number Citing Articles
1 Chan SL, Yeo W. Selecting the right patients for testing novel agents in hepatocellular carcinoma: who, when and how? Asia Pac J Clin Oncol. 2013;9:2-5. [PMID: 23418846 DOI: 10.1111/ajco.12061] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
2 Yuan SX, Yang F, Yang Y, Tao QF, Zhang J, Huang G, Yang Y, Wang RY, Yang S, Huo XS. Long noncoding RNA associated with microvascular invasion in hepatocellular carcinoma promotes angiogenesis and serves as a predictor for hepatocellular carcinoma patients' poor recurrence-free survival after hepatectomy. Hepatology. 2012;56:2231-2241. [PMID: 22706893 DOI: 10.1002/hep.25895] [Cited by in Crossref: 262] [Cited by in F6Publishing: 271] [Article Influence: 29.1] [Reference Citation Analysis]
3 Aravalli RN. Development of microRNA therapeutics for hepatocellular carcinoma. Diagnostics. 2013;3:170-191. [PMID: 26835673 DOI: 10.3390/diagnostics3010170] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
4 Shang M, Xu X, Zhang M, Yang H. Long non-coding RNA linc-ITGB1 promotes cell proliferation and migration in human hepatocellular carcinoma cells. Exp Ther Med 2017;14:4687-92. [PMID: 29201168 DOI: 10.3892/etm.2017.5143] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
5 Rebbani K, Ezzikouri S, Marchio A, Kandil M, Pineau P, Benjelloun S. MDM2 285G>C and 344T>A gene variants and their association with hepatocellular carcinoma: a Moroccan case-control study. Infect Agent Cancer 2014;9:11. [PMID: 24708820 DOI: 10.1186/1750-9378-9-11] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
6 Liu W, Wang N, Lu M, Du XJ, Xing BC. MBD2 as a novel marker associated with poor survival of patients with hepatocellular carcinoma after hepatic resection. Mol Med Rep 2016;14:1617-23. [PMID: 27315121 DOI: 10.3892/mmr.2016.5404] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
7 Zhou L, Du Y, Kong L, Zhang X, Chen Q. Identification of molecular target genes and key pathways in hepatocellular carcinoma by bioinformatics analysis. Onco Targets Ther 2018;11:1861-9. [PMID: 29670361 DOI: 10.2147/OTT.S156737] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
8 Wang Y, Zhang C, Zhang P, Guo G, Jiang T, Zhao X, Jiang J, Huang X, Tong H, Tian Y. Serum exosomal microRNAs combined with alpha-fetoprotein as diagnostic markers of hepatocellular carcinoma. Cancer Med. 2018;7:1670-1679. [PMID: 29573235 DOI: 10.1002/cam4.1390] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 12.8] [Reference Citation Analysis]
9 Shehata F, Abdel Monem N, Sakr M, Kasem S, Balbaa M. Epidermal growth factor, its receptor and transforming growth factor-β1 in the diagnosis of HCV-induced hepatocellular carcinoma. Med Oncol 2013;30:673. [PMID: 23912699 DOI: 10.1007/s12032-013-0673-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
10 Allain C, Angenard G, Clément B, Coulouarn C. Integrative Genomic Analysis Identifies the Core Transcriptional Hallmarks of Human Hepatocellular Carcinoma. Cancer Res 2016;76:6374-81. [PMID: 27634755 DOI: 10.1158/0008-5472.CAN-16-1559] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
11 Zhang Y, Fan W, Wu J, Dong J, Cui Z. Association of caveolin-1 protein expression with hepatocellular carcinoma: a meta-analysis and literature review. Cancer Manag Res 2019;11:5113-22. [PMID: 31239768 DOI: 10.2147/CMAR.S194033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
12 Anestopoulos I, Voulgaridou GP, Georgakilas AG, Franco R, Pappa A, Panayiotidis MI. Epigenetic therapy as a novel approach in hepatocellular carcinoma. Pharmacol Ther. 2015;145:103-119. [PMID: 25205159 DOI: 10.1016/j.pharmthera.2014.09.005] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
13 Bakiri L, Hamacher R, Graña O, Guío-Carrión A, Campos-Olivas R, Martinez L, Dienes HP, Thomsen MK, Hasenfuss SC, Wagner EF. Liver carcinogenesis by FOS-dependent inflammation and cholesterol dysregulation. J Exp Med 2017;214:1387-409. [PMID: 28356389 DOI: 10.1084/jem.20160935] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 7.6] [Reference Citation Analysis]
14 Zhang HJ, Yao DF, Yao M, Huang H, Wu W, Yan MJ, Yan XD, Chen J. Expression characteristics and diagnostic value of annexin A2 in hepatocellular carcinoma. World J Gastroenterol 2012; 18(41): 5897-5904 [PMID: 23139605 DOI: 10.3748/wjg.v18.i41.5897] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
15 Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology 2014;272:635-54. [PMID: 25153274 DOI: 10.1148/radiol.14132361] [Cited by in Crossref: 236] [Cited by in F6Publishing: 202] [Article Influence: 29.5] [Reference Citation Analysis]
16 Dong Z, Yao M, Zhang H, Wang L, Huang H, Yan M, Wu W, Yao D. Inhibition of Annexin A2 gene transcription is a promising molecular target for hepatoma cell proliferation and metastasis. Oncol Lett 2014;7:28-34. [PMID: 24348815 DOI: 10.3892/ol.2013.1663] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
17 Guo Y, Ma J, Wu L, Wang Q, Li X, Li X, Zhang Y, Zhang J, Yao L, Zhang J. Hyperthermia-induced NDRG2 upregulation inhibits the invasion of human hepatocellular carcinoma via suppressing ERK1/2 signaling pathway. PLoS One. 2013;8:e61079. [PMID: 23630579 DOI: 10.1371/journal.pone.0061079] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
18 Rao CV, Asch AS, Yamada HY. Frequently mutated genes/pathways and genomic instability as prevention targets in liver cancer. Carcinogenesis. 2017;38:2-11. [PMID: 27838634 DOI: 10.1093/carcin/bgw118] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 9.3] [Reference Citation Analysis]
19 Mizuguchi T, Mitaka T, Hirata K. Role of Branched Chain Amino Acids in Cellular and Organ Damage: The Prognostic Significance of the Preoperative Branched Chain Amino Acid to Tyrosine Ratio. In: Rajendram R, Preedy VR, Patel VB, editors. Branched Chain Amino Acids in Clinical Nutrition. New York: Springer; 2015. pp. 65-77. [DOI: 10.1007/978-1-4939-1914-7_5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
20 Xia W, Ni J, Zhuang J, Qian L, Wang P, Wang J. MiR-103 regulates hepatocellular carcinoma growth by targeting AKAP12. The International Journal of Biochemistry & Cell Biology 2016;71:1-11. [DOI: 10.1016/j.biocel.2015.11.017] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 4.2] [Reference Citation Analysis]
21 Chan SL, Mok T, Ma BB. Management of hepatocellular carcinoma: beyond sorafenib. Curr Oncol Rep. 2012;14:257-266. [PMID: 22434314 DOI: 10.1007/s11912-11012-10233-11910] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Kubota N, Ojima H, Hatano M, Yamazaki K, Masugi Y, Tsujikawa H, Fujii-Nishimura Y, Ueno A, Kurebayashi Y, Shinoda M, Kitago M, Abe Y, Kitagawa Y, Sakamoto M. Clinicopathological features of hepatocellular carcinoma with fatty change: Tumors with macrovesicular steatosis have better prognosis and aberrant expression patterns of perilipin and adipophilin. Pathol Int 2020;70:199-209. [PMID: 31930673 DOI: 10.1111/pin.12889] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Bisteau X, Caldez MJ, Kaldis P. The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations. Cancers (Basel) 2014;6:79-111. [PMID: 24419005 DOI: 10.3390/cancers6010079] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 5.5] [Reference Citation Analysis]
24 Del Vecchio F, Gallo F, Di Marco A, Mastroiaco V, Caianiello P, Zazzeroni F, Alesse E, Tessitore A. Bioinformatics approach to predict target genes for dysregulated microRNAs in hepatocellular carcinoma: study on a chemically-induced HCC mouse model. BMC Bioinformatics 2015;16:408. [PMID: 26652480 DOI: 10.1186/s12859-015-0836-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
25 Gao Q, Shi Y, Wang X, Zhou J, Qiu S, Fan J. Translational medicine in hepatocellular carcinoma. Front Med. 2012;6:122-133. [PMID: 22573220 DOI: 10.1007/s11684-012-0193-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
26 Guo Y, Li X, Sun X, Wang J, Yang X, Zhou X, Liu X, Liu W, Yuan J, Yao L, Li X, Shen L. Combined Aberrant Expression of NDRG2 and LDHA Predicts Hepatocellular Carcinoma Prognosis and Mediates the Anti-tumor Effect of Gemcitabine. Int J Biol Sci 2019;15:1771-86. [PMID: 31523182 DOI: 10.7150/ijbs.35094] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
27 Jianmin DM, Yan ZM, Yandong WM, Hongyu ZM, Xiang JM. Clinical Value of Contrast-enhanced Ultrasound in Differential Diagnosis of Early Hepatocellular Carcinoma and Dysplastic Nodules. Advanced Ultrasound in Diagnosis and Therapy 2017;1:10. [DOI: 10.37015/audt.2018.180009] [Reference Citation Analysis]
28 Yu J, Ren X, Chen Y, Liu P, Wei X, Li H, Ying G, Chen K, Winkler H, Hao X. Dysfunctional activation of neurotensin/IL-8 pathway in hepatocellular carcinoma is associated with increased inflammatory response in microenvironment, more epithelial mesenchymal transition in cancer and worse prognosis in patients. PLoS One. 2013;8:e56069. [PMID: 23418512 DOI: 10.1371/journal.pone.0056069] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
29 Puszyk WM, Trinh TL, Chapple SJ, Liu C. Linking metabolism and epigenetic regulation in development of hepatocellular carcinoma. Lab Invest 2013;93:983-90. [PMID: 23917878 DOI: 10.1038/labinvest.2013.94] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
30 Bhullar KS, Jha A, Rupasinghe HP. Novel carbocyclic curcumin analog CUR3d modulates genes involved in multiple apoptosis pathways in human hepatocellular carcinoma cells. Chem Biol Interact 2015;242:107-22. [PMID: 26409325 DOI: 10.1016/j.cbi.2015.09.020] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
31 Ozen E, Gozukizil A, Erdal E, Uren A, Bottaro DP, Atabey N. Heparin inhibits Hepatocyte Growth Factor induced motility and invasion of hepatocellular carcinoma cells through early growth response protein 1. PLoS One. 2012;7:e42717. [PMID: 22912725 DOI: 10.1371/journal.pone.0042717] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
32 Cui X, Hu ZP, Li Z, Gao PJ, Zhu JY. Overexpression of chaperonin containing TCP1, subunit 3 predicts poor prognosis in hepatocellular carcinoma. World J Gastroenterol 2015; 21(28): 8588-8604 [PMID: 26229401 DOI: 10.3748/wjg.v21.i28.8588] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
33 Zhou Y, Jing X, Zhang X, Ding J, Wang Y, Zhou H, Zhang Q, Chen Y, Yue W. Combining the Arterial Phase of Contrast-Enhanced Ultrasonography, Gadoxetic Acid-Enhanced Magnetic Resonance Imaging and Diffusion-Weighted Imaging in the Diagnosis of Hepatic Nodules ≤20 mm in Patients with Cirrhosis. Ultrasound in Medicine & Biology 2019;45:693-701. [DOI: 10.1016/j.ultrasmedbio.2018.10.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
34 Berasain C, Nicou A, Garcia-Irigoyen O, Latasa MU, Urtasun R, Elizalde M, Salis F, Perugorría MJ, Prieto J, Recio JA. Epidermal growth factor receptor signaling in hepatocellular carcinoma: inflammatory activation and a new intracellular regulatory mechanism. Dig Dis. 2012;30:524-531. [PMID: 23108309 DOI: 10.1159/000341705] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
35 Bacolod MD, Das SK, Sokhi UK, Bradley S, Fenstermacher DA, Pellecchia M, Emdad L, Sarkar D, Fisher PB. Examination of Epigenetic and other Molecular Factors Associated with mda-9/Syntenin Dysregulation in Cancer Through Integrated Analyses of Public Genomic Datasets. Adv Cancer Res 2015;127:49-121. [PMID: 26093898 DOI: 10.1016/bs.acr.2015.04.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
36 Liu D, Zhi L, Ma M, Qiao D, Wang M, Wang Y, Jin B, Li A, Liu G, Zhang Y, Song Y, Zhang H. Primarily screening and analyzing ESTs differentially expressed in rats' primary liver cancer. Chin J Cancer Res 2013;25:71-8. [PMID: 23372344 DOI: 10.3978/j.issn.1000-9604.2012.12.03] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
37 Kong FY, Wei X, Zhou K, Hu W, Kou YB, You HJ, Liu XM, Zheng KY, Tang RX. Bioinformatics Analysis Reveals Distinct Molecular Characteristics of Hepatitis B-Related Hepatocellular Carcinomas from Very Early to Advanced Barcelona Clinic Liver Cancer Stages. PLoS One 2016;11:e0158286. [PMID: 27454179 DOI: 10.1371/journal.pone.0158286] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
38 Chan SL, Mok T, Ma BB. Management of hepatocellular carcinoma: beyond sorafenib. Curr Oncol Rep. 2012;14:257-266. [PMID: 22434314 DOI: 10.1007/s11912-012-0233-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
39 Bozkaya G, Korhan P, Cokaklı M, Erdal E, Sağol O, Karademir S, Korch C, Atabey N. Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis. Mol Cancer 2012;11:64. [PMID: 22962849 DOI: 10.1186/1476-4598-11-64] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
40 Takagi K, Takayama T, Midorikawa Y, Hasegawa H, Ochiai T, Moriguchi M, Higaki T, Soma M, Nagase H, Fujiwara K. Cell division cycle 34 is highly expressed in hepatitis C virus-positive hepatocellular carcinoma with favorable phenotypes. Biomed Rep 2017;7:41-6. [PMID: 28685058 DOI: 10.3892/br.2017.912] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
41 Xu J, Ding T, He Q, Yu X, Wu W, Jia W, Yun J, Zhang Y, Shi M, Shao C, Pan W, Yin X, Min J, Zhuang S, Zheng L. An in situ molecular signature to predict early recurrence in hepatitis B virus-related hepatocellular carcinoma. Journal of Hepatology 2012;57:313-21. [DOI: 10.1016/j.jhep.2012.03.027] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
42 Ding J, Wang H. Multiple interactive factors in hepatocarcinogenesis. Cancer Lett. 2014;346:17-23. [PMID: 24374016 DOI: 10.1016/j.canlet.2013.12.024] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 7.0] [Reference Citation Analysis]
43 Lendvai G, Kiss A, Kovalszky I, Schaff Z. [MicroRNAs in hepatocarcinogenesis]. Orv Hetil 2012;153:978-89. [PMID: 22714032 DOI: 10.1556/OH.2012.29387] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
44 Chen W, Zhang HJ, Gu X, Shi Y, Qian Q, Yao DF, Lu SL. Overexpression of annexin A2 in hepatic tissue and serum of patients with HBV-associated hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2014; 22(9): 1207-1213 [DOI: 10.11569/wcjd.v22.i9.1207] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 Hsu WH, Chang CC, Huang KW, Chen YC, Hsu SL, Wu LC, Tsou AP, Lai JM, Huang CY. Evaluation of the medicinal herb Graptopetalum paraguayense as a treatment for liver cancer. PLoS One 2015;10:e0121298. [PMID: 25849560 DOI: 10.1371/journal.pone.0121298] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
46 Roccarina D, Majumdar A, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis. Cochrane Database Syst Rev. 2017;3:CD011649. [PMID: 28281295 DOI: 10.1002/14651858.cd011649.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
47 Chan SL, Yeo W. Targeted therapy of hepatocellular carcinoma: Present and future: Novel treatment for liver cancer. Journal of Gastroenterology and Hepatology 2012;27:862-72. [DOI: 10.1111/j.1440-1746.2012.07096.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 5.6] [Reference Citation Analysis]
48 Eso Y, Marusawa H. Novel approaches for molecular targeted therapy against hepatocellular carcinoma: Molecular targeted therapy for liver cancer. Hepatol Res 2018;48:597-607. [DOI: 10.1111/hepr.13181] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 9.0] [Reference Citation Analysis]
49 Lin WP, Xing KL, Fu JC, Ling YH, Li SH, Yu WS, Zhang YF, Zhong C, Wang JH, Chen ZY, Lu LH, Wei W, Guo RP. Development and Validation of a Model Including Distinct Vascular Patterns to Estimate Survival in Hepatocellular Carcinoma. JAMA Netw Open 2021;4:e2125055. [PMID: 34515782 DOI: 10.1001/jamanetworkopen.2021.25055] [Reference Citation Analysis]
50 Majumdar A, Roccarina D, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Management of people with early- or very early-stage hepatocellular carcinoma: An attempted network meta-analysis. Cochrane Database Syst Rev. 2017;3:CD011650. [PMID: 28351116 DOI: 10.1002/14651858.cd011650.pub2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
51 Jin K, Lu M, Liu F, Gu J, Du X, Xing B. N-WASP is highly expressed in hepatocellular carcinoma and associated with poor prognosis. Surgery 2013;153:518-25. [DOI: 10.1016/j.surg.2012.08.067] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
52 Korhan P, Erdal E, Kandemiş E, Cokaklı M, Nart D, Yılmaz F, Can A, Atabey N. Reciprocal activating crosstalk between c-Met and caveolin 1 promotes invasive phenotype in hepatocellular carcinoma. PLoS One 2014;9:e105278. [PMID: 25148256 DOI: 10.1371/journal.pone.0105278] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]